Actively Recruiting
Follow-up Cohort of Patients With Antiphospholipid Syndrome
Led by University Hospital, Rouen · Updated on 2025-09-17
200
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying Antiphospholipid Syndrome (APS), a rare condition marked by blood clots and pregnancy complications linked to persistent antiphospholipid antibodies. APS can be primary or secondary to autoimmune diseases like lupus and is associated with increased risks of heart attacks, strokes, and artery diseases. Current treatments mainly focus on blood thinning, but new therapies like direct oral anticoagulants and hydroxychloroquine are being explored due to limited data on recurrence rates and treatment safety. This study follows a group of patients diagnosed with APS according to the 2006 Sydney classification. It is an observational cohort study tracking patients retrospectively and prospectively to understand clot recurrence rates, treatment complications, and overall health outcomes. Patients receive standard care with routine follow-up visits every 3 to 12 months over five years, without changes to their usual treatment. Participants will attend consultations at intervals based on their individual situations, with assessments to monitor clot recurrence, complications, risk factors, mortality, and morbidity. The study aims to provide better data on APS progression and treatment safety, helping to design future clinical trials. Follow-up visits and evaluations will not alter the usual disease management, ensuring patient care remains consistent throughout the study.
CONDITIONS
Brief Title
Follow-up Cohort of Patients With Antiphospholipid Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients over 18 years of age and under 75 years of age
- Diagnosis of Antiphospholipid Syndrome meeting the 2006 Sydney classification
You will not qualify if you...
- Patients younger than 18 years or older than 75 years
- Patients with a syndrome not meeting the 2006 Sydney classification
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 5 years
Participants are followed up in consultation every 3 months, 6 months to 1 year, for up to 5 years depending on the situation to observe thrombotic recurrence, treatment complications, risk factors, mortality, and morbidity.
Consultation visits every 3 months, 6 months, or 1 year depending on the situation
Trial Site Locations
Total: 1 location
1
University hospital of Rouen
Rouen, France, 76031
Actively Recruiting
Research Team
S
Sébastien SM MIRANDA, Doctor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here